Anticoagulant therapy for atrial fibrillation. Recommendations from major studies.
The role of antithrombotic therapy in reducing thromboembolic complications in patients with chronic atrial fibrillation has been clarified by the results of four major randomized and placebo-controlled trials. Patients with rheumatic heart disease complicated by atrial fibrillation should receive long-term warfarin therapy to reduce the risk of stroke unless an absolute contraindication exists. Patients with nonrheumatic atrial fibrillation should also be treated with low-dose warfarin therapy, especially if high-risk features for thromboembolism exist. In patients who have contraindications to warfarin therapy and in young patients with lone atrial fibrillation or paroxysmal atrial fibrillation, therapy with 325 mg of aspirin a day is preferred. Ongoing trials directly comparing aspirin and warfarin will provide additional insight into the optimal role of these antithrombotic agents in patients with atrial fibrillation.
Kahn
J K
JK
Michigan Heart and Vascular Institute, St Joseph Mercy Hospital, Ann Arbor.
D000208:Acute Disease; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000209:etiology; D002908:Chronic Disease; D004554:Electric Countershock / Q000009:adverse effects / Q000592:standards; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design / Q000592:standards; D012214:Rheumatic Heart Disease / Q000150:complications; D012307:Risk Factors; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014859:Warfarin; D001241:Aspirin